Evidence map›Paper›PMID 41053771›Full record

Trial reportBMC complementary medicine and therapies2025

Efficacy and safety of curcumin in patients with hand osteoarthritis: a pilot double-blinded randomised controlled trial.

Panithan Tuntiyatorn, Chawanin Lerspongpaibool, Thepparat Kanchanathepsak, Ittirat Watcharananan, Tulyapruek Tawonsawatruk

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Panithan TuntiyatornChakri Naruebodindra Medical Institute, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Samut prakan, Thailand.
Chawanin LerspongpaiboolDepartment of Orthopaedics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Thepparat KanchanathepsakDepartment of Orthopaedics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Ittirat WatcharanananDepartment of Orthopaedics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Tulyapruek TawonsawatrukDepartment of Orthopaedics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Tulyapruek@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurcumin, a substance in Turmeric spices, has been shown to exhibit anti-inflammatory and chondroprotective properties in several preclinical studies. However, there is limited research on the efficacy and side effects of oral curcumin in treating hand osteoarthritis. Thus, the primary aim of this pilot study was to assess the therapeutic effects and potential adverse effects of curcumin in patients with hand osteoarthritis, specifically in terms of pain reduction, improvement in functional outcomes, and relevant blood test parameters.

methodThis pilot prospective double-blind, randomized controlled trial included patients over 50 years old diagnosed with hand osteoarthritis. Participants received a three-month oral administration of either a turmeric capsule containing curcumin (170 mg/day) or a placebo. The outcomes measures included the Visual Analogue Scale (VAS) for pain, the Disabilities of Arm, Shoulder, and Hand (DASH) score, hand grip and pinch strength, as well as side effects and blood tests at one, two, three, and six months.

resultsTwenty-seven patients were enrolled in this study-13 in the curcumin group and 14 in the placebo group. Baseline characteristics were similar between both groups. Although patients in the curcumin group showed reductions in VAS pain scores and improvements in DASH scores after one month, the differences were not statistically significant. However, by the third month, patients in the curcumin group demonstrated significant reductions in VAS pain scores at rest and during activity compared to the baseline scores, with mean differences of 1.37 ± 0.64 (p-value = 0.032) and 1.74 ± 0.73 (p-value = 0.017), respectively. Additionally, their DASH scores improved significantly with a mean difference of 11.84 ± 5.88 (p = 0.044). One patient in the curcumin group experienced gastrointestinal (GI) side effects, leading to withdrawal from the study, but no other adverse effects were reported.

conclusionBased on the results of this pilot study, the authors conclude that a three-month regimen of low-dose oral curcumin may improve pain and functional scores in patients with hand osteoarthritis compared to placebo. However, GI discomfort remains a potential side effect to monitor. Overall, curcumin appears to be a safe and feasible alternative treatment option for hand osteoarthritis, and a larger, definitive randomised controlled trial is warranted.

trial registrationThe trial has been registered in the Thai Clinical Trials Registry(TCTR) database. The identification number is TCTR20210929003.

Indexed as

CurcuminOsteoarthritisAgedCurcumaDouble-Blind MethodFemaleHandHumansMaleMiddle AgedPain MeasurementPilot ProjectsProspective StudiesCurcuminCurcuma longaCurcuminHand osteoarthritisOsteoarthritis of handTumeric

Identifiers

PMID41053771
PMCPMC12502247

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.